Coexpression cluster:C64: Difference between revisions
From FANTOM5_SSTAR
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
|ontology_enrichment_disease=DOID:8692!3.34e-14!31;DOID:1240!8.36e-11!39 | |ontology_enrichment_disease=DOID:8692!3.34e-14!31;DOID:1240!8.36e-11!39 | ||
|ontology_enrichment_uberon=UBERON:0007023!1.96e-39!115;UBERON:0002390!4.12e-09!102;UBERON:0003061!4.12e-09!102;UBERON:0002193!2.14e-08!112;UBERON:0001049!3.68e-08!57;UBERON:0005068!3.68e-08!57;UBERON:0006241!3.68e-08!57;UBERON:0007135!3.68e-08!57;UBERON:0000178!1.46e-07!15;UBERON:0000179!1.46e-07!15;UBERON:0000463!1.46e-07!15;UBERON:0003080!3.22e-07!42;UBERON:0002780!6.52e-07!41;UBERON:0001890!6.52e-07!41;UBERON:0006240!6.52e-07!41 | |ontology_enrichment_uberon=UBERON:0007023!1.96e-39!115;UBERON:0002390!4.12e-09!102;UBERON:0003061!4.12e-09!102;UBERON:0002193!2.14e-08!112;UBERON:0001049!3.68e-08!57;UBERON:0005068!3.68e-08!57;UBERON:0006241!3.68e-08!57;UBERON:0007135!3.68e-08!57;UBERON:0000178!1.46e-07!15;UBERON:0000179!1.46e-07!15;UBERON:0000463!1.46e-07!15;UBERON:0003080!3.22e-07!42;UBERON:0002780!6.52e-07!41;UBERON:0001890!6.52e-07!41;UBERON:0006240!6.52e-07!41 | ||
|pathway_enrichment=0.000408482490749907;0.0392915054717728;2;19;Glycosaminoglycan degradation (KEGG):00531!5.97745207276168e-05;0.0189186358102907;9;1138;Metabolic pathways (KEGG):01100!1.1404796683487e-05;0.00721923630064726;4;88;Hematopoietic cell lineage (KEGG):04640!0.00022831642013065;0.0337020096262946;3;75;B cell receptor signaling pathway (KEGG):04662!0.000266208606842769;0.0337020096262946;3;79;Fc epsilon RI signaling pathway (KEGG):04664!0.000500639824850358;0.0396131261412846;2;21;Nicotine Activity on Dopaminergic Neurons (Wikipathways):WP1602!0.000178329108259578;0.0337020096262946;3;69;Kit Receptor Signaling Pathway (Wikipathways):WP304!0.000434503220066997;0.0392915054717728;5;406;{GRB2,414} (Static Module):NA | |||
}} | }} |
Revision as of 15:04, 13 July 2012
Full id: C64_Mast_chronic_acute_immature_chorionic_Basophils_Dendritic
Phase1 CAGE Peaks
Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data
p.value | FDR | nGenes | nPathway | Name |
---|---|---|---|---|
0.000408482490749907 | 0.0392915054717728 | 2 | 19 | Glycosaminoglycan degradation (KEGG):00531 |
5.97745207276168e-05 | 0.0189186358102907 | 9 | 1138 | Metabolic pathways (KEGG):01100 |
1.1404796683487e-05 | 0.00721923630064726 | 4 | 88 | Hematopoietic cell lineage (KEGG):04640 |
0.00022831642013065 | 0.0337020096262946 | 3 | 75 | B cell receptor signaling pathway (KEGG):04662 |
0.000266208606842769 | 0.0337020096262946 | 3 | 79 | Fc epsilon RI signaling pathway (KEGG):04664 |
0.000500639824850358 | 0.0396131261412846 | 2 | 21 | Nicotine Activity on Dopaminergic Neurons (Wikipathways):WP1602 |
0.000178329108259578 | 0.0337020096262946 | 3 | 69 | Kit Receptor Signaling Pathway (Wikipathways):WP304 |
0.000434503220066997 | 0.0392915054717728 | 5 | 406 | {GRB2,414} (Static Module):NA |
Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data
GO ID | GO name | FDR corrected p-value |
---|---|---|
GO:0044459 | plasma membrane part | 6.2062644451875e-06 |
GO:0016020 | membrane | 1.99708048901291e-05 |
GO:0044425 | membrane part | 2.24528527276455e-05 |
GO:0005886 | plasma membrane | 5.88970166873583e-05 |
GO:0005887 | integral to plasma membrane | 8.69980399503271e-05 |
GO:0031226 | intrinsic to plasma membrane | 8.69980399503271e-05 |
GO:0019370 | leukotriene biosynthetic process | 0.000287815957469235 |
GO:0043450 | alkene biosynthetic process | 0.000287815957469235 |
GO:0016021 | integral to membrane | 0.000361066901149375 |
GO:0031224 | intrinsic to membrane | 0.000364225469261048 |
GO:0006691 | leukotriene metabolic process | 0.000555625194960442 |
GO:0043449 | alkene metabolic process | 0.000555625194960442 |
GO:0046456 | icosanoid biosynthetic process | 0.000621438032861417 |
GO:0007267 | cell-cell signaling | 0.000754890752863334 |
GO:0000267 | cell fraction | 0.000754890752863334 |
GO:0019863 | IgE binding | 0.000754890752863334 |
GO:0007154 | cell communication | 0.000754890752863334 |
GO:0005624 | membrane fraction | 0.000989206728433819 |
GO:0007268 | synaptic transmission | 0.0013557281985812 |
GO:0006690 | icosanoid metabolic process | 0.0013557281985812 |
GO:0009897 | external side of plasma membrane | 0.0013557281985812 |
GO:0044464 | cell part | 0.0013557281985812 |
GO:0015012 | heparan sulfate proteoglycan biosynthetic process | 0.00196070523304531 |
GO:0019226 | transmission of nerve impulse | 0.00200124420200425 |
GO:0030201 | heparan sulfate proteoglycan metabolic process | 0.00329908471299796 |
GO:0006633 | fatty acid biosynthetic process | 0.00341927754194821 |
GO:0016053 | organic acid biosynthetic process | 0.00464928351396739 |
GO:0046394 | carboxylic acid biosynthetic process | 0.00464928351396739 |
GO:0031420 | alkali metal ion binding | 0.00482183126304149 |
GO:0048066 | pigmentation during development | 0.00482183126304149 |
GO:0019865 | immunoglobulin binding | 0.00482183126304149 |
GO:0031402 | sodium ion binding | 0.0062541307242965 |
GO:0030317 | sperm motility | 0.00693857836307523 |
GO:0030166 | proteoglycan biosynthetic process | 0.00693857836307523 |
GO:0019932 | second-messenger-mediated signaling | 0.00843897173742179 |
GO:0018193 | peptidyl-amino acid modification | 0.0109609675054676 |
GO:0006029 | proteoglycan metabolic process | 0.0130802208270065 |
GO:0005901 | caveola | 0.0130802208270065 |
GO:0032501 | multicellular organismal process | 0.0130802208270065 |
GO:0007165 | signal transduction | 0.0134360306419679 |
GO:0008484 | sulfuric ester hydrolase activity | 0.0148766916356193 |
GO:0030955 | potassium ion binding | 0.01496247897959 |
GO:0009986 | cell surface | 0.0164736719574906 |
GO:0005529 | sugar binding | 0.017641471836277 |
GO:0019722 | calcium-mediated signaling | 0.0181091204358118 |
GO:0009605 | response to external stimulus | 0.0181091204358118 |
GO:0005020 | stem cell factor receptor activity | 0.0181091204358118 |
GO:0004464 | leukotriene-C4 synthase activity | 0.0181091204358118 |
GO:0019983 | interleukin-9 binding | 0.0181091204358118 |
GO:0004261 | cathepsin G activity | 0.0181091204358118 |
GO:0004398 | histidine decarboxylase activity | 0.0181091204358118 |
GO:0008449 | N-acetylglucosamine-6-sulfatase activity | 0.0181091204358118 |
GO:0004919 | interleukin-9 receptor activity | 0.0181091204358118 |
GO:0004423 | iduronate-2-sulfatase activity | 0.0181091204358118 |
GO:0005688 | snRNP U6 | 0.0181091204358118 |
GO:0019372 | lipoxygenase pathway | 0.0181091204358118 |
GO:0030324 | lung development | 0.0181091204358118 |
GO:0018108 | peptidyl-tyrosine phosphorylation | 0.0181091204358118 |
GO:0030323 | respiratory tube development | 0.0185015770210732 |
GO:0006814 | sodium ion transport | 0.0185015770210732 |
GO:0018212 | peptidyl-tyrosine modification | 0.0188880257382508 |
GO:0005057 | receptor signaling protein activity | 0.0191159753849701 |
GO:0044272 | sulfur compound biosynthetic process | 0.0191236807095353 |
GO:0045121 | lipid raft | 0.0196647675455426 |
GO:0005515 | protein binding | 0.0204422281645964 |
GO:0030203 | glycosaminoglycan metabolic process | 0.0216145800295139 |
GO:0006631 | fatty acid metabolic process | 0.0218354579783783 |
GO:0006022 | aminoglycan metabolic process | 0.0218354579783783 |
GO:0009611 | response to wounding | 0.0228039576697707 |
GO:0008146 | sulfotransferase activity | 0.0228039576697707 |
GO:0016740 | transferase activity | 0.0228039576697707 |
GO:0045055 | regulated secretory pathway | 0.0230246989895528 |
GO:0048518 | positive regulation of biological process | 0.0230246989895528 |
GO:0005509 | calcium ion binding | 0.023409137407097 |
GO:0001812 | positive regulation of type I hypersensitivity | 0.023409137407097 |
GO:0032632 | interleukin-3 production | 0.023409137407097 |
GO:0032998 | Fc-epsilon receptor I complex | 0.023409137407097 |
GO:0042223 | interleukin-3 biosynthetic process | 0.023409137407097 |
GO:0019767 | IgE receptor activity | 0.023409137407097 |
GO:0032997 | Fc receptor complex | 0.023409137407097 |
GO:0001810 | regulation of type I hypersensitivity | 0.023409137407097 |
GO:0045401 | positive regulation of interleukin-3 biosynthetic process | 0.023409137407097 |
GO:0001867 | complement activation, lectin pathway | 0.023409137407097 |
GO:0016572 | histone phosphorylation | 0.023409137407097 |
GO:0007195 | dopamine receptor, adenylate cyclase inhibiting pathway | 0.023409137407097 |
GO:0001820 | serotonin secretion | 0.023409137407097 |
GO:0045399 | regulation of interleukin-3 biosynthetic process | 0.023409137407097 |
GO:0016782 | transferase activity, transferring sulfur-containing groups | 0.0256688207315552 |
GO:0044444 | cytoplasmic part | 0.0256688207315552 |
GO:0007166 | cell surface receptor linked signal transduction | 0.0263190028266626 |
GO:0030246 | carbohydrate binding | 0.0263190028266626 |
GO:0009058 | biosynthetic process | 0.0263190028266626 |
GO:0043406 | positive regulation of MAP kinase activity | 0.0263190028266626 |
GO:0005882 | intermediate filament | 0.0263190028266626 |
GO:0045111 | intermediate filament cytoskeleton | 0.0263190028266626 |
GO:0006468 | protein amino acid phosphorylation | 0.0263190028266626 |
GO:0044262 | cellular carbohydrate metabolic process | 0.0263190028266626 |
GO:0003001 | generation of a signal involved in cell-cell signaling | 0.0263190028266626 |
GO:0016404 | 15-hydroxyprostaglandin dehydrogenase (NAD+) activity | 0.0263190028266626 |
GO:0008273 | calcium, potassium:sodium antiporter activity | 0.0263190028266626 |
GO:0048286 | alveolus development | 0.0263190028266626 |
GO:0043306 | positive regulation of mast cell degranulation | 0.0263190028266626 |
GO:0002712 | regulation of B cell mediated immunity | 0.0263190028266626 |
GO:0001880 | Mullerian duct regression | 0.0263190028266626 |
GO:0002863 | positive regulation of inflammatory response to antigenic stimulus | 0.0263190028266626 |
GO:0045921 | positive regulation of exocytosis | 0.0263190028266626 |
GO:0045425 | positive regulation of granulocyte macrophage colony-stimulating factor biosynthetic process | 0.0263190028266626 |
GO:0043302 | positive regulation of leukocyte degranulation | 0.0263190028266626 |
GO:0002885 | positive regulation of hypersensitivity | 0.0263190028266626 |
GO:0019763 | immunoglobulin receptor activity | 0.0263190028266626 |
GO:0002866 | positive regulation of acute inflammatory response to antigenic stimulus | 0.0263190028266626 |
GO:0015015 | heparan sulfate proteoglycan biosynthetic process, enzymatic modification | 0.0263190028266626 |
GO:0002675 | positive regulation of acute inflammatory response | 0.0263190028266626 |
GO:0002889 | regulation of immunoglobulin mediated immune response | 0.0263190028266626 |
GO:0002891 | positive regulation of immunoglobulin mediated immune response | 0.0263190028266626 |
GO:0002714 | positive regulation of B cell mediated immunity | 0.0263190028266626 |
GO:0006959 | humoral immune response | 0.0281782614966539 |
GO:0006813 | potassium ion transport | 0.0285051202749976 |
GO:0015672 | monovalent inorganic cation transport | 0.0297760356794334 |
GO:0004872 | receptor activity | 0.0297760356794334 |
GO:0002526 | acute inflammatory response | 0.0299129190516467 |
GO:0008324 | cation transmembrane transporter activity | 0.0299129190516467 |
GO:0050877 | neurological system process | 0.0299129190516467 |
GO:0060033 | anatomical structure regression | 0.0299129190516467 |
GO:0045423 | regulation of granulocyte macrophage colony-stimulating factor biosynthetic process | 0.0299129190516467 |
GO:0019369 | arachidonic acid metabolic process | 0.0299129190516467 |
GO:0002861 | regulation of inflammatory response to antigenic stimulus | 0.0299129190516467 |
GO:0003870 | 5-aminolevulinate synthase activity | 0.0299129190516467 |
GO:0002673 | regulation of acute inflammatory response | 0.0299129190516467 |
GO:0016749 | N-succinyltransferase activity | 0.0299129190516467 |
GO:0060158 | dopamine receptor, phospholipase C activating pathway | 0.0299129190516467 |
GO:0002864 | regulation of acute inflammatory response to antigenic stimulus | 0.0299129190516467 |
GO:0043304 | regulation of mast cell degranulation | 0.0299129190516467 |
GO:0002883 | regulation of hypersensitivity | 0.0299129190516467 |
GO:0016068 | type I hypersensitivity | 0.0299129190516467 |
GO:0015016 | [heparan sulfate]-glucosamine N-sulfotransferase activity | 0.0299129190516467 |
GO:0050778 | positive regulation of immune response | 0.0307121634142691 |
GO:0002684 | positive regulation of immune system process | 0.0309662108255466 |
GO:0006790 | sulfur metabolic process | 0.0309662108255466 |
GO:0007200 | G-protein signaling, coupled to IP3 second messenger (phospholipase C activating) | 0.032148810727699 |
GO:0032787 | monocarboxylic acid metabolic process | 0.0327559154739174 |
GO:0006954 | inflammatory response | 0.0337907850744836 |
GO:0043405 | regulation of MAP kinase activity | 0.0338803630712217 |
GO:0043300 | regulation of leukocyte degranulation | 0.0338803630712217 |
GO:0032604 | granulocyte macrophage colony-stimulating factor production | 0.0338803630712217 |
GO:0008504 | monoamine transmembrane transporter activity | 0.0338803630712217 |
GO:0042253 | granulocyte macrophage colony-stimulating factor biosynthetic process | 0.0338803630712217 |
GO:0050850 | positive regulation of calcium-mediated signaling | 0.0338803630712217 |
GO:0001786 | phosphatidylserine binding | 0.0338803630712217 |
GO:0015057 | thrombin receptor activity | 0.0338803630712217 |
GO:0042221 | response to chemical stimulus | 0.0343279384958619 |
GO:0007167 | enzyme linked receptor protein signaling pathway | 0.0343279384958619 |
GO:0003712 | transcription cofactor activity | 0.0347317852046899 |
GO:0022414 | reproductive process | 0.0354068430583468 |
GO:0048522 | positive regulation of cellular process | 0.0354068430583468 |
GO:0050776 | regulation of immune response | 0.0354068430583468 |
GO:0004713 | protein-tyrosine kinase activity | 0.0354068430583468 |
GO:0019900 | kinase binding | 0.0354342921625397 |
GO:0016563 | transcription activator activity | 0.0354342921625397 |
GO:0007596 | blood coagulation | 0.0354342921625397 |
GO:0002682 | regulation of immune system process | 0.0354342921625397 |
GO:0032403 | protein complex binding | 0.0354342921625397 |
GO:0050817 | coagulation | 0.0354342921625397 |
GO:0007275 | multicellular organismal development | 0.0354342921625397 |
GO:0006026 | aminoglycan catabolic process | 0.0354342921625397 |
GO:0005071 | transmembrane receptor protein serine/threonine kinase signaling protein activity | 0.0354342921625397 |
GO:0002437 | inflammatory response to antigenic stimulus | 0.0354342921625397 |
GO:0015991 | ATP hydrolysis coupled proton transport | 0.0354342921625397 |
GO:0002524 | hypersensitivity | 0.0354342921625397 |
GO:0006027 | glycosaminoglycan catabolic process | 0.0354342921625397 |
GO:0002438 | acute inflammatory response to antigenic stimulus | 0.0354342921625397 |
GO:0015844 | monoamine transport | 0.0354342921625397 |
GO:0016310 | phosphorylation | 0.0359834330155454 |
GO:0030659 | cytoplasmic vesicle membrane | 0.0359834330155454 |
GO:0051240 | positive regulation of multicellular organismal process | 0.0359834330155454 |
GO:0007599 | hemostasis | 0.0359834330155454 |
GO:0044433 | cytoplasmic vesicle part | 0.0371035625221812 |
GO:0009308 | amine metabolic process | 0.0381162387370599 |
GO:0002252 | immune effector process | 0.0382047842911111 |
GO:0008610 | lipid biosynthetic process | 0.0382047842911111 |
GO:0050848 | regulation of calcium-mediated signaling | 0.0382047842911111 |
GO:0016748 | succinyltransferase activity | 0.0382047842911111 |
GO:0031116 | positive regulation of microtubule polymerization | 0.0382047842911111 |
GO:0002448 | mast cell mediated immunity | 0.0382047842911111 |
GO:0050998 | nitric-oxide synthase binding | 0.0382047842911111 |
GO:0043303 | mast cell degranulation | 0.0382047842911111 |
GO:0012506 | vesicle membrane | 0.0390008978266377 |
GO:0012505 | endomembrane system | 0.0397854453469242 |
GO:0016023 | cytoplasmic membrane-bound vesicle | 0.0397854453469242 |
GO:0030170 | pyridoxal phosphate binding | 0.0397854453469242 |
GO:0035295 | tube development | 0.0397854453469242 |
GO:0022804 | active transmembrane transporter activity | 0.0397854453469242 |
GO:0031988 | membrane-bound vesicle | 0.0397854453469242 |
GO:0043299 | leukocyte degranulation | 0.0397854453469242 |
GO:0008508 | bile acid:sodium symporter activity | 0.0397854453469242 |
GO:0007567 | parturition | 0.0397854453469242 |
GO:0005890 | sodium:potassium-exchanging ATPase complex | 0.0397854453469242 |
GO:0045576 | mast cell activation | 0.0397854453469242 |
GO:0030321 | transepithelial chloride transport | 0.0397854453469242 |
GO:0030318 | melanocyte differentiation | 0.0397854453469242 |
GO:0031112 | positive regulation of microtubule polymerization or depolymerization | 0.0397854453469242 |
GO:0050931 | pigment cell differentiation | 0.0397854453469242 |
GO:0005513 | detection of calcium ion | 0.0397854453469242 |
GO:0031113 | regulation of microtubule polymerization | 0.0397854453469242 |
GO:0044249 | cellular biosynthetic process | 0.0404087223046943 |
GO:0006807 | nitrogen compound metabolic process | 0.0409674568023372 |
GO:0030001 | metal ion transport | 0.0415910646563362 |
GO:0042802 | identical protein binding | 0.0421285244510891 |
GO:0006810 | transport | 0.0421285244510891 |
GO:0050878 | regulation of body fluid levels | 0.0421285244510891 |
GO:0007242 | intracellular signaling cascade | 0.0421727043001538 |
GO:0002824 | positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 0.0422459383313623 |
GO:0051018 | protein kinase A binding | 0.0422459383313623 |
GO:0042730 | fibrinolysis | 0.0422459383313623 |
GO:0002821 | positive regulation of adaptive immune response | 0.0422459383313623 |
GO:0002444 | myeloid leukocyte mediated immunity | 0.0422459383313623 |
GO:0048015 | phosphoinositide-mediated signaling | 0.0430945792495447 |
GO:0001525 | angiogenesis | 0.0430945792495447 |
GO:0007243 | protein kinase cascade | 0.0439723224692827 |
GO:0042060 | wound healing | 0.0439723224692827 |
GO:0048856 | anatomical structure development | 0.0442478902729819 |
GO:0003008 | system process | 0.0442478902729819 |
GO:0005684 | U2-dependent spliceosome | 0.0442478902729819 |
GO:0002705 | positive regulation of leukocyte mediated immunity | 0.0442478902729819 |
GO:0015125 | bile acid transmembrane transporter activity | 0.0442478902729819 |
GO:0046785 | microtubule polymerization | 0.0442478902729819 |
GO:0015988 | energy coupled proton transport, against electrochemical gradient | 0.0442478902729819 |
GO:0042423 | catecholamine biosynthetic process | 0.0442478902729819 |
GO:0002708 | positive regulation of lymphocyte mediated immunity | 0.0442478902729819 |
GO:0016051 | carbohydrate biosynthetic process | 0.0464342122190085 |
GO:0044446 | intracellular organelle part | 0.0470218110545163 |
GO:0044422 | organelle part | 0.0471998514227728 |
GO:0045860 | positive regulation of protein kinase activity | 0.0471998514227728 |
GO:0031349 | positive regulation of defense response | 0.0471998514227728 |
GO:0002699 | positive regulation of immune effector process | 0.0471998514227728 |
GO:0050729 | positive regulation of inflammatory response | 0.0471998514227728 |
GO:0051234 | establishment of localization | 0.0474879696980125 |
GO:0048513 | organ development | 0.0479506261104194 |
GO:0033674 | positive regulation of kinase activity | 0.0482779721737636 |
GO:0008283 | cell proliferation | 0.0482779721737636 |
GO:0048514 | blood vessel morphogenesis | 0.0485772734950791 |
GO:0030145 | manganese ion binding | 0.0485772734950791 |
GO:0051347 | positive regulation of transferase activity | 0.0485772734950791 |
GO:0048731 | system development | 0.0485772734950791 |
GO:0004672 | protein kinase activity | 0.0485772734950791 |
GO:0001937 | negative regulation of endothelial cell proliferation | 0.0485772734950791 |
GO:0030641 | cellular hydrogen ion homeostasis | 0.0485772734950791 |
GO:0002706 | regulation of lymphocyte mediated immunity | 0.0485772734950791 |
GO:0030195 | negative regulation of blood coagulation | 0.0485772734950791 |
GO:0002703 | regulation of leukocyte mediated immunity | 0.0485772734950791 |
Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>
Ontology term | p-value | n |
---|---|---|
myeloid cell | 4.36e-20 | 112 |
common myeloid progenitor | 4.36e-20 | 112 |
hematopoietic stem cell | 7.32e-12 | 172 |
angioblastic mesenchymal cell | 7.32e-12 | 172 |
hematopoietic oligopotent progenitor cell | 8.24e-11 | 165 |
hematopoietic multipotent progenitor cell | 8.24e-11 | 165 |
hematopoietic cell | 9.47e-11 | 182 |
myeloid leukocyte | 2.23e-07 | 76 |
Ontology term | p-value | n |
---|---|---|
adult organism | 1.96e-39 | 115 |
hematopoietic system | 4.12e-09 | 102 |
blood island | 4.12e-09 | 102 |
hemolymphoid system | 2.14e-08 | 112 |
neural tube | 3.68e-08 | 57 |
neural rod | 3.68e-08 | 57 |
future spinal cord | 3.68e-08 | 57 |
neural keel | 3.68e-08 | 57 |
blood | 1.46e-07 | 15 |
haemolymphatic fluid | 1.46e-07 | 15 |
organism substance | 1.46e-07 | 15 |
anterior neural tube | 3.22e-07 | 42 |
regional part of forebrain | 6.52e-07 | 41 |
forebrain | 6.52e-07 | 41 |
future forebrain | 6.52e-07 | 41 |
Ontology term | p-value | n |
---|---|---|
myeloid leukemia | 3.34e-14 | 31 |
leukemia | 8.36e-11 | 39 |
Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data
Novel motifs
JASPAR motifs
Motifs | -log10(p-value) |
---|---|
{{{tfbs_overrepresentation_jaspar}}} |
ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data
No analysis results for this cluster
Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data
"{{{coexpression_dpi_cluster_scores_median}}}" is not a number.